Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- Status
- RECRUITING
- Phase
- PHASE2
Expanded Access to Venetoclax
- Status
- AVAILABLE
- Phase
- N/A
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Status
- RECRUITING
- Phase
- PHASE1
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE3
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE1
A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
- Status
- COMPLETED
- Phase
- PHASE2
Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1
Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
- Status
- COMPLETED
- Phase
- PHASE3
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL
- Status
- COMPLETED
- Phase
- PHASE2